文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

成纤维细胞激活蛋白靶向放射性药物治疗:177Lu、90Y和225Ac标记3BP-3940在21种晚期恶性肿瘤中的首次经验

Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy Using 177Lu-, 90Y-, and 225Ac-Labeled 3BP-3940: First Experience in 21 Different Advanced Malignancies.
PubMed 文献 · J Nucl Med · 2026-06-01

治疗耐受性良好,多数不良事件轻微;可评估患者客观缓解率为66.7%,疾病控制率为80.4%,中位总生存期为7.0个月。

要点

  • 3BP-3940 FRT在多种晚期实体瘤中可行且耐受性良好,严重不良事件未报告。
  • 可评估患者客观缓解率66.7%,疾病控制率80.4%。
  • 全队列中位总生存期7.0个月,提示生存获益。

核心结论

  • 3BP-3940 FRT使用177Lu、90Y或225Ac单药或串联治疗对终末期癌症患者可行,耐受性相对良好且无严重不良效应。
  • 3BP-3940 FRT显示有利的生物分布(肾脏蓄积极低)、显著肿瘤摄取和长滞留,在晚期侵袭性经重度治疗的转移性腺癌和肉瘤中观察到客观缓解。
  • 观察到的生存获益似乎非常有前景,需进一步前瞻性随机更大队列更长随访验证。

研究设计与样本

  • 患者经[68Ga]Ga-3BP-3940 PET/CT确认肿瘤摄取后,接受227周期177Lu、90Y或225Ac标记的3BP-3940治疗,单药或串联治疗。
  • 毒性按CTCAE v5.0分级,评估治疗反应,采用Kaplan-Meier分析计算自治疗开始的总生存期。

主要发现

  • 不良事件大多轻微:疼痛16%、疼痛加剧13%、恶心13%、呕吐7%、部分脱发8%、疲劳加重5%、腹泻3%、头痛2%、短暂发热5%。
  • 一例胰腺癌患者接受9.73 GBq [177Lu]Lu-3BP-3940,吸收剂量:脑37 mGy、肺168 mGy、健康肝组织86 mGy、胰腺142 mGy、肾脏265 mGy、原发肿瘤2200 mGy。
  • 2周期FRT后肿瘤反应:完全缓解3.0%、部分缓解51.5%、疾病稳定15.2%、疾病进展30.3%。
  • 任何FRT周期后最佳肿瘤反应(51例可评估):完全缓解2/51(3.9%)、部分缓解32/51(62.7%)、疾病稳定7/51(13.7%)、疾病进展8/51(15.7%)、混合反应2/51(3.9%),客观缓解率66.7%,疾病控制率80.4%。
  • 全队列自FRT开始的中位总生存期为7.0个月。

关键数值与推荐

  • 客观缓解率66.7%(部分缓解62.7%+完全缓解3.9%),疾病控制率80.4%(客观缓解+疾病稳定13.7%)。
  • 全队列中位总生存期7.0个月。
  • 剂量学示例:9.73 GBq [177Lu]Lu-3BP-3940使原发肿瘤吸收剂量达2200 mGy,肾脏265 mGy。

临床怎么用

  • 对于经[68Ga]Ga-3BP-3940 PET/CT确认肿瘤摄取的终末期癌症患者,可考虑使用177Lu、90Y或225Ac标记的3BP-3940进行FAP靶向放射性药物治疗。
  • 治疗前应通过FAP靶向PET/CT筛选高摄取患者,治疗中按CTCAE v5.0监测毒性。
  • 该治疗在重度经治的转移性腺癌和肉瘤中显示较高客观缓解率和疾病控制率,但需更大规模前瞻性随机研究确认生存获益。

局限性

  • 部分患者接受了额外的标准治疗,可能影响反应和生存评估。
  • 研究为首次人体经验,样本量有限且随访时间有限。
  • 需进一步前瞻性随机更大队列更长随访分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibroblast activation protein (FAP) is an attractive target for molecular precision imaging and therapy, given its specific tumor expression across various cancer types. We report first-in-human results using a FAP-targeted cyclic peptide, 3BP-3940, labeled with 177Lu, 90Y, and 225Ac for FAP-targeted radiopharmaceutical therapy (FRT) in patients with end-stage cancer. Methods: Eighty-eight patients with 21 distinct advanced metastatic solid tumor types received 227 cycles of 177Lu-, 90Y-, 225Ac-labeled 3BP-3940, either alone or as tandem treatment, FRT between March 2021 and January 2025, after confirmation of tumor uptake by [68Ga]Ga-3BP-3940 PET/CT. Toxicity was graded using Common Terminology Criteria for Adverse Events version 5.0. Treatment response was assessed, and survival from treatment initiation was calculated using Kaplan-Meier analysis. Results: Administrations of [177Lu]Lu-, [90Y]Y-, and [225Ac]Ac-3BP-3940 were well tolerated, and most adverse events were mild (pain 16%, pain flare 13%, nausea 13%, vomiting 7%, partial alopecia 8%, intensified fatigue 5%, diarrhea 3%, headache 2%, and transient fever 5%). No other clinically relevant adverse symptoms or pharmacologic effects were reported. Dosimetry in a patient with pancreatic cancer receiving 9.73 GBq of [177Lu]Lu-3BP-3940 showed absorbed doses of 37 mGy in the brain, 168 mGy in the lungs, 86 mGy in healthy liver tissue, 142 mGy in the pancreas, 265 mGy in the kidneys, and 2200 mGy for the primary tumor. Some patients underwent additional treatments as their standard of care. After 2 cycles of FRT, tumor responses were complete remission (3.0%), partial remission (51.5%), stable disease (15.2%), and progressive disease (30.3%). The best tumor response observed after any FRT cycle was 2 of 51 (3.9%) with complete remission, 32 of 51 (62.7%) with partial remission, 7 of 51 (13.7%) with stable disease, 8 of 51 (15.7%) with progressive disease, and 2 of 51 (3.9%) with a mixed response, yielding an objective response rate of 66.7% and a disease control rate of 80.4%. For the entire cohort, median overall survival was 7.0 mo from FRT initiation. Conclusion: 3BP-3940 FRT is feasible with 177Lu, 90Y, or 225Ac alone or as tandem treatment for patients with end-stage cancer. Treatments were relatively well tolerated without serious adverse effects. 3BP-3940 FRT demonstrated favorable biodistribution (exceptionally very low renal accumulation), significant tumor uptake, and long retention with very high tumor-to-background ratios, demonstrating objective responses in advanced, aggressive, and heavily pretreated metastatic adenocarcinomas and sarcomas. The observed survival benefit appears to be highly promising. Further prospective randomized analysis in a larger cohort with longer follow-up is warranted.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Baum RP, Zhao T, Jakobsson V, et al. Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy Using 177Lu-, 90Y-, and 225Ac-Labeled 3BP-3940: First Experience in 21 Different Advanced Malignancies. J Nucl Med. 2026. PMID: 42225357. doi:10.2967/jnumed.125.271129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。